Safety -Good systemic tolerability was observed at all dose levels. The only adverse event (AE) of note was local irritation and mild pain at the infusion site, which cleared within 1-2 days. As this appears to be related to the local concentration in the vein at the infusion site, it is not expected to be an issue in haemodialysis patients as the drug will be administered into the tubing delivering blood to the dialysis column. There were no serious AEs, no deaths, and no withdrawals due to AEs during the study. No meaningful differences were observed for data reported from the clinical laboratory tests, 12-Lead ECGs, physical examinations, Visual Analogue Scale (VAS) tests, and Orthostatic hypotension tests (Table 2) . Ionised calcium levels were measured, although several errors occurred in terms of sampling and analysis. The data suggested a possible dose-related decrease as shown in Figure 3 . There were however no clinical features of hypocalcaemia or clinically relevant increases in QTc observed with any of the three doses evaluated. Furthermore, in the intended therapeutic situation (infusion during dialysis), the ionized Ca concentration in the blood will be stabilised by the Ca concentration in the dialysis fluid. 
INTRODUCTION
SNF472 is an intravenous (i.v.) formulation of myo-inositol-hexaphosphate (phytate). It is a selective calcification inhibitor exerting its effect through binding to hydroxyapatite crystal (HAP) growing sites. It is being developed, as an orphan drug, for the treatment of calciphylaxis. It is also being developed to inhibit the progression of cardiovascular calcification in patients with end stage renal disease on haemodialysis, to prevent cardiovascular events (including mortality). It has been extensively studied in non-clinical models for efficacy, safety, pharmacokinetics and toxicity, and shows a promising profile supporting progression to studies in humans. Sixteen healthy male subjects were divided into two cohorts (C) with 8 subjects each. Cohorts were randomised in a 6:2 ratio to receive SNF472 or placebo, respectively. Each cohort participated in two treatment periods (TP). Subjects were dosed in sequential, consecutive subgroups within each cohort. The first subgroup consisted of two sentinel subjects; one subject received SNF472 and one subject received placebo. Subgroup 2 was dosed at least 24 hours after Subgroup 1. C1 and C2 were interlocking cohorts, such that TPs alternated between cohorts. Successive TPs between C1 and C2 were separated by at least 7 days. The administered SNF472 doses were: 0.5 mg/kg, 5 mg/kg, 9 mg/kg and 12.5 mg/kg. The study included a screening visit, two treatment periods, and a followup visit. The maximum expected duration for an individual subject in this part of the study, including screening and follow-up, was approximately 7 weeks.
Fasting subjects received a single i.v. dose of either SNF472 or placebo over a 4-hour period in the morning of day 1 of each TP. Safety monitoring (vital signs, 12 lead ECG, and safety laboratory assessments), serial blood, and urine samples for PK were performed at specific time points during the TPs. Extensive ECG assessments were undertaken and subjects were monitored for hypocalcaemia by clinical signs and blood calcium measurements during TPs. Subjects were discharged from the Clinical Unit (CU) on day 3 of each TP after all the assessments had been completed. Subjects returned to the CU on day 4 after each TP for PK blood samples and safety assessments, and on day 7 for safety assessments. Subjects returned to the CU on day 14 after TP2 for a follow-up visit.
SNF472 was quantified in all PK samples by tandem mass spectrometry after separation in gradient reversed-phase chromatography PD assessed the potential for ex vivo formation of HAP crystals in plasma samples obtained at baseline and around the t max at the end of the 4-hour of infusion. Pharmacodynamics -PD assessments showed an 80% inhibition at 5 mg/kg SNF472 on the blood potential to calcify, which appeared to be a plateau as the effects were similar for the 9 mg/kg and 12.5 mg/kg doses (Figure 4 ). 
